0001140361-16-087737.txt : 20161123 0001140361-16-087737.hdr.sgml : 20161123 20161123133503 ACCESSION NUMBER: 0001140361-16-087737 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161121 FILED AS OF DATE: 20161123 DATE AS OF CHANGE: 20161123 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200915291 FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: BUILDING 227, TETRICUS SCIENCE PARK STREET 2: PORTON DOWN CITY: SALISBURY, WILTSHIRE STATE: X0 ZIP: SP4 0JQ BUSINESS PHONE: 44 0 1980 753002 MAIL ADDRESS: STREET 1: BUILDING 227, TETRICUS SCIENCE PARK STREET 2: PORTON DOWN CITY: SALISBURY, WILTSHIRE STATE: X0 ZIP: SP4 0JQ FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Therapeutics, Inc. DATE OF NAME CHANGE: 20140916 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery, Inc DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery Inc DATE OF NAME CHANGE: 20060105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Renzi David CENTRAL INDEX KEY: 0001631294 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36830 FILM NUMBER: 162015923 MAIL ADDRESS: STREET 1: C/O CARBYLAN THERAPEUTICS, INC. STREET 2: 3181 PORTER DRIVE CITY: PALO ALTO STATE: CA ZIP: 94304 4 1 doc1.xml FORM 4 X0306 4 2016-11-21 1 0001348911 KalVista Pharmaceuticals, Inc. CBYL 0001631294 Renzi David C/O CARBYLAN THERAPEUTICS, INC. 39899 BALENTINE DRIVE, SUITE 200 NEWARK CA 94560 1 1 0 0 President & CEO Common Stock 2016-11-21 4 M 0 36640 7.84 A 36640 D Common Stock 2016-11-21 4 F 0 33454 8.5932 D 3186 D Common Stock 2016-11-21 4 U 0 3186 8.5932 D 0 D Stock Option (Right to Buy) 7.84 2016-11-21 4 M 0 36640 0.00 D 2023-06-06 Common Stock 36640 0 D The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction. The option is fully vested and exercisable. /s/ David Renzi 2016-11-23